Bardin Laurent, Colpaert Francis C
Centre de Recherche Pierre-Fabre, 17 Avenue Jean Moulin, Castres Cédex F-81106, France.
Eur J Pain. 2004 Jun;8(3):253-61. doi: 10.1016/j.ejpain.2003.09.002.
We here studied the involvement of spinally located 5-HT(1A) and opioid receptors, in the paradoxical effects that their activation can produce on nociception. Intrathecal (i.t.) injection of the 5-HT(1A) receptor agonist 8-hydroxy-2-[di-n-propylamino] tetralin (8-OH-DPAT) (1-10 microg) induced analgesic effects in the formalin model of tonic pain whereas in the paw pressure test, it decreased the vocalization threshold. In this latter test, i.t. 8-OH-DPAT also markedly reduced the analgesic effect of systemic morphine (5-10 mg/kg, s.c.). At 10 microg, 8-OH-DPAT totally abolished the effect of 5 mg/kg of morphine; this inhibitory effect was antagonized by pre-treatment with 0.63 mg/kg of the 5-HT(1A) antagonist WAY-100635 (N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]-ethyl]-N-(2-pyridinyl)-cyclohexanecarboxamide-trihydrochloride). In contrast, the i.t. injection of WAY-100635 (1-10 microg) dose-dependently potentiated the antinociceptive activity of a dose of morphine (2.5 mg/kg, s.c.). Furthermore, WAY-100635 (10 microg, i.t.) potentiated morphine analgesia in morphine-tolerant rats. These findings demonstrate that 5-HT(1A) receptor agonists can act in the spinal cord to produce both hyper- and hypo-algesic effects and play a major role in the opioid analgesia and tolerance.
我们在此研究了脊髓中5-羟色胺(5-HT)1A受体和阿片受体在其激活后对伤害感受产生的矛盾效应中的作用。鞘内注射5-HT1A受体激动剂8-羟基-2-[二正丙基氨基]四氢萘(8-OH-DPAT)(1 - 10微克)在福尔马林持续性疼痛模型中诱导镇痛作用,而在爪部压力试验中,它降低了发声阈值。在后者的试验中,鞘内注射8-OH-DPAT还显著降低了全身吗啡(5 - 10毫克/千克,皮下注射)的镇痛作用。在10微克时,8-OH-DPAT完全消除了5毫克/千克吗啡的作用;这种抑制作用可被预先注射0.63毫克/千克的5-HT1A拮抗剂WAY-100635(N-[2-[4-(2-甲氧基苯基)-1-哌嗪基]-乙基]-N-(2-吡啶基)-环己烷甲酰胺-三盐酸盐)所拮抗。相反,鞘内注射WAY-100635(1 - 10微克)剂量依赖性地增强了一定剂量吗啡(2.5毫克/千克,皮下注射)的抗伤害感受活性。此外,WAY-100635(10微克,鞘内注射)增强了吗啡耐受大鼠的吗啡镇痛作用。这些发现表明,5-HT1A受体激动剂可在脊髓中发挥作用,产生痛觉过敏和痛觉减退两种效应,并在阿片类镇痛和耐受中起主要作用。